IP Library Granted Patent US 12,709,778
Granted Patent B2
US 12,709,778 · App. 17/938,640 · Granted Aug 18, 2026

High-plex guide pooling for nucleic acid detection

Inventors: Matthew Verosloff (South San Francisco, CA); Clare Fasching (Redwood City, CA); Carley Gelenter Hendriks (Burlingame, CA); Xin Miao (Mountain View, CA); James Paul Broughton (South San Francisco, CA); Lucas Benjamin Harrington (San Francisco, CA); Janice Sha Chen (San Francisco, CA)
Assignee: Mammoth Biosciences, Inc.
C12Q1/689C12N9/22C12Q1/6806C12Q1/6816C12Q1/6844C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,778
App. No.
17/938,640
Filed
Oct 6, 2022
Granted
Aug 18, 2026
Kind
B2
Art Unit
1645
USPC
435/7.32
Abstract

Provided herein, in certain embodiments, are various methods, reagents, and devices for detection of multiple target nucleic acids in a sample, or multiple segments of a target nucleic acid in a sample, using a programmable nuclease. In certain embodiments, the present disclosure provides compositions of pools of guide nucleic acids, programmable nucleases, and detector nucleic acids and methods of using said compositions for detection of different segments of one target nucleic acid or different target nucleic acids in a sample.

Claims (28)

1 . A composition comprising a programmable nuclease, a detector nucleic acid, and a pool of guide nucleic acids comprising greater than 20 distinct guide nucleic acid sequences, wherein:

(i) at least one guide nucleic acid of the pool hybridizes to a segment of a target nucleic acid;

(ii) the detector nucleic acid comprises a detection moiety that produces a detectable signal responsive to cleavage by the programmable nuclease upon formation of a complex comprising the programmable nuclease, the at least one guide nucleic acid, and the segment of the target nucleic acid; and

(iii) a total concentration of the pool of guide nucleic acids is about 400 nM to about 2000 nM (2 μM).

2 . The composition of claim 1 , wherein the pool of guide nucleic acids comprises at least 50 distinct guide nucleic acid sequences, at least 100 distinct guide nucleic acid sequences, at least 500 distinct guide nucleic acid sequences, or at least 1000 distinct guide nucleic acid sequences.

3 . The composition of claim 1 , wherein the pool of guide nucleic acids comprises at least two guide nucleic acids that hybridize to a different segment of the target nucleic acid.

4 . The composition of claim 1 , wherein a guide nucleic acid of the pool of guide nucleic acids has a sequence selected from a group of tiled guide nucleic acids that correspond to nucleic acids of the target nucleic acid.

5 . The composition of claim 4 , wherein:

a) the tiled guide nucleic acids are sequential along the target nucleic acid upon hybridization to the target nucleic acid;

b) the tiled guide nucleic acids are non-sequential along the target nucleic acid upon hybridization to the target nucleic acid;

c) the tiled guide nucleic acids are overlapping along the target nucleic acid upon hybridization to the target nucleic acid; or

d) any combination thereof.

6 . The composition of claim 1 , wherein the target nucleic acid is from a pathogen.

7 . The composition of claim 1 , wherein at least two guide nucleic acids of the pool of guide nucleic acids hybridize to segments of distinct target nucleic acids.

8 . The composition of claim 7 , wherein at least two target nucleic acids of the distinct target nucleic acids are from different pathogens.

9 . The composition of claim 6 , wherein the pathogen is a virus, a bacterium, a fungus, a protozoan, or a worm.

10 . The composition of claim 1 , wherein at least two guide nucleic acids of the pool of guide nucleic acids differs from one another by at least one base.

11 . The composition of claim 1 , wherein the total concentration of the pool of guide nucleic acids is about 400 nM, about 1000 nM (1 μM), or about 2000 nM (2 μM).

12 . The composition of claim 1 , wherein each guide nucleic acid of the pool of guide nucleic acids comprises from 20 to 50 bases.

13 . The composition of claim 1 , wherein the programmable nuclease is a Type V CRISPR-Cas enzyme or a Type VI CRISPR-Cas enzyme.

14 . The composition of claim 1 , wherein the target nucleic acid is DNA or RNA.

15 . The composition of claim 1 , wherein the composition further comprises the target nucleic acid.

16 . The composition of claim 15 , wherein the target nucleic acid comprises distinct target nucleic acids.

17 . A method of assaying for a segment of a target nucleic acid in a sample, the method comprising:

contacting the sample to the composition of claim 1 ; and

assaying for the detectable signal.

18 . The method of claim 17 , further comprising reverse transcribing the target nucleic acid, amplifying the target nucleic acid, in vitro transcribing the target nucleic acid, or any combination thereof.

19 . The method of claim 18 , wherein the amplifying is isothermal amplification.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: MIAO, XIN; BROUGHTON, JAMES PAUL; HARRINGTON, LUCAS BENJAMIN; CHEN, JANICE SHA; VEROSLOFF, MATTHEW; FASCHING, CLARE; HENDRIKS, CARLEY GELENTER
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 061429/0052 →
Continuity (3)
Continuation PCTUS2021026719 · Apr 9, 2021
Provisional Application 63008500 · Apr 10, 2020
Related Publication 20240084401A1 · Mar 14, 2024
References Cited (22)
US 11453907B2 · Zhang et al. · 2022 [cited by applicant]
US 11639523B2 · Zhang et al. · 2023 [cited by applicant]
US 20190367924A1 · Khalili et al. · 2019 [cited by applicant]
US 20210292823A1 · Zhang et al. · 2021 [cited by applicant]
WO WO2015122967A1 · 2015 [cited by examiner]
WO WO2019104058A1 · 2019 [cited by applicant]
WO WO2020028729A1 · 2020 [cited by applicant]
WO WO2020124050A1 · 2020 [cited by examiner]
WO WO2020186231A2 · 2020 [cited by applicant]
WO WO2021163584A1 · 2021 [cited by applicant]
WO WO2022132955A2 · 2022 [cited by applicant]
Jacobi et al. Methods 121-122 (2017) 16-28. [cited by examiner]
Kellner et al. Nat Protoc 14, 2986-3012 (2019). [cited by examiner]
Liu et al., “Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities,” [cited by applicant]
Murugan et al., “The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit,” [cited by applicant]
Tambe et al., “RNA Binding and HEPN-Nuclease Activation Are Decoupled in CRISPR-Cas13a,” [cited by applicant]
Ackerman et al., “Massively multiplexed nucleic acid detection with Cas13,” [cited by applicant]
Broughton et al., “CRISPR-Cas12-based detection of SARS-CoV-2,” [cited by applicant]
Chen et al., “CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity,” [cited by applicant]
Chen et al., “Supplementary Materials for CRISPR-Cas 12a target binding unleashes indiscriminate single-stranded DNase activity,” [cited by applicant]
Gootenberg et al., “Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6,” [cited by applicant]
Gootenberg et al., “Supplementary Materisla for Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6,” [cited by applicant]